23andMe

2018 Rock Health Summit Opens with Panel Featuring DotLab CEO

Retrieved on: 
Thursday, October 18, 2018
23andMe, Genetics, Anne Wojcicki, Rock Health, Bioinformatics, Biology

SAN FRANCISCO, Oct. 18, 2018 /PRNewswire/ --On Tuesday, DotLab CEO Heather Bowerman spoke on the opening panel of the 2018 Rock Health Summit .

Key Points: 
  • SAN FRANCISCO, Oct. 18, 2018 /PRNewswire/ --On Tuesday, DotLab CEO Heather Bowerman spoke on the opening panel of the 2018 Rock Health Summit .
  • Rock Health is one of Silicon Valley's leading digital health venture capital funds, and the panel was moderated by Rock Health's Director of Research, Megan Zweig.
  • This year's Summit featured innovators such as Anne Wojcicki (Co-founder and CEO, 23andMe) and Karen DeSalvo, MD (Former Acting Assistant Secretary at the U.S. Department of Health and Human Services).
  • In their 2018 Digital Health Midyear Funding Review , Rock Health reports on the continued upward trajectory of venture funding for digital health, reaching $3.4 billion during the first half of 2018.

Scripps Research Translational Institute Collaborates with Seqster To Bring Genetic Risk Scores With Health Data

Retrieved on: 
Tuesday, October 16, 2018
Genetics, Biology, Applied genetics, Bioinformatics, 23andMe, Coronary artery disease, Genomic counseling, Pathway Genomics

Scientists at the SRTI have developed a smartphone-powered research study that seeks to understand how receiving personal genetic risk information impacts health decisions.

Key Points: 
  • Scientists at the SRTI have developed a smartphone-powered research study that seeks to understand how receiving personal genetic risk information impacts health decisions.
  • The MyGeneRank app allows individuals with genetic data from the consumer genomics company, 23andMe, to obtain an estimated genetic risk score for coronary artery disease (CAD).
  • Surveys and digital health data will be used to determine if this information helped guide decision-making related to lifestyle modification and initiation of medications.
  • For more information on Seqster and how we can bring health to your members, employees or patients, please visit www.seqster.com or follow @Seqster.

Timicoin/TimiHealth Urges Consumers to Petition 23andMe and Other Genetic Testing Companies and Demand Ownership and Control of Their Genetic Data

Retrieved on: 
Thursday, August 30, 2018
Genetics, Biology, Applied genetics, Medicine, Biological databases, 23andMe, GlaxoSmithKline, Genetic testing

AUSTIN, Texas, Aug. 30, 2018 /PRNewswire/ -- Timicoin/TimiHealth ( www.timicoin.io ), the leader in genetic data ownership through its ultra secureblockchain technology is urging consumers to petition genetic testing companies like 23andMe to provide complete transparency in how they use collected genetic data and allow portability to whomever individual consumers choose to have it.

Key Points: 
  • AUSTIN, Texas, Aug. 30, 2018 /PRNewswire/ -- Timicoin/TimiHealth ( www.timicoin.io ), the leader in genetic data ownership through its ultra secureblockchain technology is urging consumers to petition genetic testing companies like 23andMe to provide complete transparency in how they use collected genetic data and allow portability to whomever individual consumers choose to have it.
  • TimiHealth launched the TimiDNA platform as a direct response to 23andMe and other genetic testing companies who are selling genetic data for unintended financial benefit without the understood permission of consumers or profit sharing with them.
  • This was highlighted by the announced $300 million dollar 50/50 partnership deal between 23andMe and GlaxoSmithKline (GSK) ( https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agre... ).
  • TimiHealth is supporting consumers who have expressed deep disappointment and anger in the misrepresentation of services for the collection and sale of their genetic DNA data through sponsorship of "Where's Your DNA?

23andMe Turns Off Consumer Access to Porting Their Genetic Data to TimiDNA, Disappointing Many Consumers

Retrieved on: 
Tuesday, August 28, 2018
Applied genetics, Genetics, Biological databases, 23andMe, Bioinformatics, Biology

( https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agre... )

Key Points: 
  • ( https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agre... )
    Since the launch of TimiDNA, thousands of requests have been received to move data from 23andMe to TimiDNA.
  • "The voice of the consumer regarding the issue of healthcare data ownership has spoken, and we continue to get numerous requests for porting data to TimiDNA," said Joyce Lignell, Chairwoman of the TimiHealth Advisory Board.
  • He cited an August 23, 2018, statement issued by 23andMe announcing a change to the 23andMe API program.
  • "By this change they have taken away the consumer's ability to control and share the very data they contributed to 23andMe," said Lignell.

Dash Genomics Launches A Personalized Alzheimer's Disease Analysis Using Genetic Data

Retrieved on: 
Tuesday, August 21, 2018
Genetics, Bioinformatics, Genomics, Biology, Applied genetics, Biological databases, 23andMe, Omics, Genomic counseling

HealthLytix has developed a proprietary, age-dependent model for assessing an individual's risk profile for developing Alzheimer's disease over their lifespan using their genetic information.

Key Points: 
  • HealthLytix has developed a proprietary, age-dependent model for assessing an individual's risk profile for developing Alzheimer's disease over their lifespan using their genetic information.
  • Dash Genomics now enables anyone who has had their genetic information provided by either 23andMe or Ancestry.com to take advantage of this unique and more comprehensive method of characterizing their risk of developing Alzheimer's disease.
  • Dash Genomics provides information to visually track risk profiles over an individual's lifespan based on their current age and submitted genetic data file.
  • Partnering with HealthLytix allows us to bring state-of-the-art scientific findings to the growing community of people with their genetic data," Dash Genomics shared in a public statement.

TimiDNA Platform Now Available Along with Two Million Timicoin Giveaway

Retrieved on: 
Wednesday, August 15, 2018
Biology, Genetics, Biotechnology, Biological databases, Applied genetics, Cryptocurrencies, Emerging technologies, 23andMe, Blockchain, DNA

1) TimiDNA now active Individuals are able to upload their DNA data from 23andMe immediately here.

Key Points: 
  • 1) TimiDNA now active Individuals are able to upload their DNA data from 23andMe immediately here.
  • TimiHealth will be giving away a total of two million Timicoins to the first 100,000 individuals who upload their DNA data to the TimiDNA platform.
  • Don't delay, get paid for your DNA and secure it in the TimiDNA blockchain here: https://timidna.timicoin.io
    3)Blockshow TimiHealth will be showcasing the TimiDNA platform at the Blockshow ( https://blockshow.com/ ) in Las Vegas August 20-21, 2018.
  • TimiHealth is the first operating blockchain designed to empower individuals through its TimiDNA platform to own, control, and monetize their genetic DNA data.

TimiDNA (LATOKEN Exchange: TMC) is First Tokenized Genetics Platform Placing Individuals First in Protecting and Monetizing Their DNA Data

Retrieved on: 
Thursday, August 9, 2018
Biology, Genetics, Applied genetics, Biological databases, 23andMe, Bioinformatics

On August 20, 2018, TimiHealth will be launching the TimiDNA platform and the Two Million Timicoin Giveaway!

Key Points: 
  • On August 20, 2018, TimiHealth will be launching the TimiDNA platform and the Two Million Timicoin Giveaway!
  • The first 100,000 individuals who upload their DNA data to the TimiDNA platform will receive 20 Timicoins.
  • TimiHealth is the first organization to truly challenge genetic research companies like 23andMe head on, with a consumer-centric model that puts individuals first in monetizing their DNA data.
  • TimiHealth will soon be announcing exciting future partnerships with DNA organizations focused on empowering consumers to control and tokenize their data.

Kalorama Information: Beyond 23andMe.com, A Direct-to-Consumer Genetic Testing Industry Emerges

Retrieved on: 
Wednesday, July 18, 2018
Genetics, Medicine, Health, Applied genetics, Alternatives to animal testing, Genetic testing, 23andMe, Direct-to-consumer advertising, Predisposition

ROCKVILLE, Md., July 18, 2018 /PRNewswire/ -- Healthcare market research firm Kalorama Information says that the global direct-to-consumer (DTC) genetic health testing market totaled $99 million in 2017.

Key Points: 
  • ROCKVILLE, Md., July 18, 2018 /PRNewswire/ -- Healthcare market research firm Kalorama Information says that the global direct-to-consumer (DTC) genetic health testing market totaled $99 million in 2017.
  • Strong growth is expected through the forecast period due to easing of the regulatory process for DTC genetic tests.
  • While 23andMe.com leads the market, Kalorama Information says part of that future growth is expected to come from new competitors, including:
    EasyDNA in Elk Grove, CA offers DNA testing for celiac disease and genetic testing for cancer and predisposition and genetic disease predisposition.
  • Kalorama Information's report, The Market for Direct-to-Consumer Genetic Testing, is available at https://www.kaloramainformation.com/Direct-Consumer-Genetic-Health-Testi... .

2018 Global Strategic Business Report: Direct-to-Consumer (DTC) Genetic Testing - High Potential Benefits, But Concerns Persist

Retrieved on: 
Thursday, July 12, 2018
Genetics, Biology, Breast cancer, Medicine, Tumor markers, Tumor suppressor genes, Medical genetics, Applied genetics, 23andMe, BRCA2, Genetic testing, BRCA

Quest Diagnostics and Inserm Launch BRCA Share, a Datashare Initiative with Open Access to BRCA1 and BRCA2 Genetic Data

Key Points: 

Quest Diagnostics and Inserm Launch BRCA Share, a Datashare Initiative with Open Access to BRCA1 and BRCA2 Genetic Data
23andMe Bags FDA Approval for Personal Genome Service, a DTC Genetic Test for Bloom Syndrome

Rigel Appoints Dean Schorno as Chief Financial Officer

Retrieved on: 
Wednesday, May 30, 2018
Economy, Business, 23andMe, Chief financial officer, NASDAQ

(Nasdaq:RIGL) today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).

Key Points: 
  • (Nasdaq:RIGL) today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
  • Mr. Schorno joins Rigel from 23andMe, Inc., the leading consumer genetics and research company, where he has been CFO since 2015.
  • During this time, Mr. Schorno led financial operations through periods of significant business and commercial growth which included significant financing and commercial transaction activity.
  • "It's an exciting time to join Rigel and support its growth," said Mr. Schorno.